Literature DB >> 18197877

Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.

Claudia Pinto Marques Souza de Oliveira1, José Tadeu Stefano, Erika Rabelo Forte de Siqueira, Leonardo Soares Silva, Daniel Ferraz de Campos Mazo, Vicência Mara Rodrigues Lima, Carlos Kioshi Furuya, Evandro Sobroza Mello, Fabrício G Souza, Fabíola Rabello, Telma Eugênio Santos, Monize Aydar Nogueira, Stephen H Caldwell, Venâncio Avancini Ferreira Alves, Flair José Carrilho.   

Abstract

AIM: There is no proven medical therapy for the treatment of non-alcoholic steatohepatitis (NASH). Oxidative stress and insulin resistance are the mechanisms that seem to be mostly involved in its pathogenesis. The aim of our study was to evaluate the efficacy of N-acetylcysteine (NAC) in combination with metformin (MTF) in improving the aminotransferases and histological parameters (steatosis, inflammation, hepatocellular ballooning, and fibrosis) after 12 months of treatment.
METHODS: Twenty consecutive patients (mean age 53 +/- 2 years [36-68] and body mass index [BMI] 29 [25-35]) with biopsy-proven NASH were enrolled in the study. NAC (1.2 g/day) and MTF (850-1000 mg/day) were given orally for 12 months. All patients underwent evaluation of serum aminotransferases, fasting lipid profile and serum glucose, anthropometric parameters, and nutritional status at 0 and 12 months. A low calorie diet was prescribed for all patients.
RESULTS: Serum alanine aminotransferase, high-density lipoprotein, insulin, and glucose concentrations and thehomeostasis model assessment-insulin resistance (HOMA-IR) index were reduced significantly at the end of study (P < 0.05). The BMI declined, but without statistical significance. Aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase, cholesterol, and triglycerides levels were not altered with the treatment. Liver steatosis and fibrosis decreased (P < 0.05), but no improvement was noted in lobular inflammation or hepatocellular ballooning. The NASH activity score was significantly improved after treatment.
CONCLUSION: Based on the biochemical and histological evidence in this pilot study, NAC in combination with MTF appears to ameliorate several aspects of NASH, including fibrosis. Further studies of this form of combination therapy are warranted to assess its potential efficacy.

Entities:  

Year:  2008        PMID: 18197877     DOI: 10.1111/j.1872-034X.2007.00215.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  34 in total

1.  Metformin: a therapeutic option for treating nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

2.  Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8.

Authors:  Ahmed Abu Shanab; Paul Scully; Orla Crosbie; Martin Buckley; Liam O'Mahony; Fergus Shanahan; Sanaa Gazareen; Eileen Murphy; Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

3.  N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis.

Authors:  January N Baumgardner; Kartik Shankar; Leah Hennings; Emanuele Albano; Thomas M Badger; Martin J J Ronis
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

4.  N-acetylcysteine (NAC) diminishes the severity of PCB 126-induced fatty liver in male rodents.

Authors:  Ian K Lai; Kiran Dhakal; Gopi S Gadupudi; Miao Li; Gabriele Ludewig; Larry W Robertson; Alicia K Olivier
Journal:  Toxicology       Date:  2012-07-21       Impact factor: 4.221

5.  A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice.

Authors:  Indrani Sinha-Hikim; Amiya P Sinha-Hikim; Ruoqing Shen; Hyun Ju Kim; H Kim; Samuel W French; Nosratola D Vaziri; Nosratola D Vaziri; Albert C Crum; Albert Crum; Tripathi B Rajavashisth; Keith C Norris
Journal:  Exp Mol Pathol       Date:  2011-05-03       Impact factor: 3.362

6.  Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease.

Authors:  Géraldine Gentric; Vanessa Maillet; Valérie Paradis; Dominique Couton; Antoine L'Hermitte; Ganna Panasyuk; Bernard Fromenty; Séverine Celton-Morizur; Chantal Desdouets
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

7.  Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.

Authors:  Melissa A Linden; Kristi T Lopez; Justin A Fletcher; E Matthew Morris; Grace M Meers; Sameer Siddique; M Harold Laughlin; James R Sowers; John P Thyfault; Jamal A Ibdah; R Scott Rector
Journal:  Appl Physiol Nutr Metab       Date:  2015-06-24       Impact factor: 2.665

Review 8.  Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.

Authors:  A Zarrinpar; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2012-10-11       Impact factor: 8.171

Review 9.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

Review 10.  Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Authors:  Lance L Stein; Mamie H Dong; Rohit Loomba
Journal:  Adv Ther       Date:  2009-11-16       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.